Welcome to our dedicated page for Verrica Pharmaceuticals SEC filings (Ticker: VRCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Verrica Pharmaceuticals’ SEC filings can feel like reviewing a clinical protocol—dense tables on R&D spend, detailed trial updates on YCANTH, and pages of license obligations. Yet those details matter when you’re judging cash runway or the odds of FDA approval. That’s where Stock Titan steps in.
Our AI reads every new document the moment it hits EDGAR and delivers plain-English answers to the questions you actually ask: “What did the latest Verrica Pharmaceuticals quarterly earnings report 10-Q filing reveal about Phase 3 costs?” or “Did any directors buy shares in yesterday’s Verrica Pharmaceuticals insider trading Form 4 transactions?” From the 10-K sections that outline manufacturing risks to 8-K material events on trial data, we tag the passages that move the stock and explain why.
- AI-powered summaries translate biotech jargon into clear insights
- Real-time alerts for Verrica Pharmaceuticals Form 4 insider transactions
- Side-by-side views of each Verrica Pharmaceuticals annual report 10-K simplified
- Keyword search across proxy statement executive compensation tables
- Automatic highlights of 8-K trial milestones and financing updates
Whether you’re monitoring Verrica Pharmaceuticals executive stock transactions Form 4 before conference data, studying cash burn in the latest 10-Q, or just need Verrica Pharmaceuticals SEC filings explained simply, Stock Titan transforms hundreds of pages into actionable paragraphs. Stop scrolling, start understanding.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 9,235,571 shares of Verrica Pharmaceuticals Inc. (VRCA), representing 9.99% of the outstanding common stock. The filing states Armistice Capital is the investment manager of the direct holder, Armistice Capital Master Fund Ltd., and exercises shared voting and dispositive power over the reported shares; Mr. Boyd, as managing member, is likewise reported with shared voting and dispositive power. The filing affirms the securities are held in the ordinary course of business and not for the purpose of changing or influencing control.
Verrica Pharmaceuticals reported consolidated results for the quarter ended June 30, 2025 showing total revenue of $12.7 million, driven by $8.2 million of license and collaboration revenue and $4.5 million of net product sales of YCANTH (VP-102). The company recorded a small net income of $0.2 million for the quarter versus a large loss in the prior-year period, but a net loss of $9.5 million for the six months ended June 30, 2025.
Cash and cash equivalents declined to $15.4 million from $46.3 million at year-end, and the balance sheet shows total debt, net of discounts and issuance costs, of $37.3 million and a derivative liability of $1.8 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern within one year unless additional financing is obtained; the Credit Agreement requires maintaining at least $10.0 million of liquidity and contains covenants that were partially waived for certain 2025 periods.
Key corporate actions include a 1-for-10 reverse stock split (effective July 24, 2025) and a June 27, 2025 amendment with Torii that accelerated an $8.0 million milestone (paid in July 2025) and sets cost-sharing and future royalty/transfer-price arrangements for a Phase 3 program for common warts.
Verrica Pharmaceuticals announced a press release reporting its financial results for the three- and six-month periods ended June 30, 2025 and disclosed details for a related conference call; that press release is furnished as Exhibit 99.1 to the current report. The filing also includes an interactive XBRL cover page file.
The company further disclosed that Nasdaq's Listing Qualifications Staff has determined the company has regained compliance with the bid price requirement under Nasdaq Listing Rule 5450(a)(1), indicating the company is currently meeting Nasdaq's listing standards for minimum bid price.
Verrica Pharmaceuticals Inc. (VRCA) filed an 8-K to disclose a Second Amendment to its March 2021 Collaboration and License Agreement with Torii Pharmaceutical Co., Ltd.
- Up-front cash: Torii will pay Verrica an $8.0 million milestone tied to the ongoing global Phase 3 trial of YCANTH (VP-102) for common warts.
- Cost-sharing: The parties will continue to split trial expenses 50/50. Torii will advance the first $40.0 million of out-of-pocket costs; Verrica will subsequently reimburse Torii for half. If expenses exceed $40 million, Verrica will fund the overage (up to a stated cap) and Torii will reimburse 50% of that excess.
- Additional milestone: Torii agreed to a separate $10.0 million cash payment upon Japanese approval of YCANTH for molluscum contagiosum—paid in cash rather than as a trial-cost offset.
- Manufacturing rights: A technology-transfer program will allow Torii to manufacture the product. Until partial transfer is complete, Torii will buy commercial supply from Verrica at transfer pricing; thereafter Verrica will receive quarterly royalties in the high-single- to low-double-digit range.
- All other material terms of the original agreement remain unchanged.
The amendment improves Verrica’s near-term liquidity via non-dilutive funding, caps some development risk, and may accelerate commercial scale-up in Japan. A press release announcing the amendment (Exhibit 99.1) was issued on July 1, 2025.
FAQ
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
What is the market cap of Verrica Pharmaceuticals (VRCA)?
